Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Columbus, OH
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Portland, OR
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Tipton, PA
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Tipton, PA
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Carrollton, TX
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Dallas, TX
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Dallas, TX
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
San Antonio, TX
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Burke, VA
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Burke, VA
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Manassas, VA
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Manassas, VA
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Port Orchard, WA
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Port Orchard, WA
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Madison, WI
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Madison, WI
Effect of Febuxostat on Blood Pressure
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions
e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions
Status: Enrolling
Updated:  8/3/2015
Brigham and Women's Hosp
mi
from
Boston, MA
e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions
e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions
Status: Enrolling
Updated: 8/3/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Physical Inactivity and Insulin Resistance in Skeletal Muscle.
Physical Inactivity and Insulin Resistance in Skeletal Muscle.
Status: Enrolling
Updated:  8/10/2015
Harry S. Truman Memorial Veterans' Hospital
mi
from
Columbia, MO
Physical Inactivity and Insulin Resistance in Skeletal Muscle.
Physical Inactivity and Insulin Resistance in Skeletal Muscle.
Status: Enrolling
Updated: 8/10/2015
Harry S. Truman Memorial Veterans' Hospital
mi
from
Columbia, MO
Click here to add this to my saved trials
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Status: Enrolling
Updated:  8/10/2015
VA Connecticut Health Care System
mi
from
West Haven, CT
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Status: Enrolling
Updated: 8/10/2015
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Status: Enrolling
Updated:  8/10/2015
Richard L. Roudebush VA Medical Center
mi
from
Indianapolis, IN
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Status: Enrolling
Updated: 8/10/2015
Richard L. Roudebush VA Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Muscle Shoals, AL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Chandler, AZ
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigator Site
mi
from
Buena Park, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigator Site
mi
from
Buena Park, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Fair Oaks, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Long Beach, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Orangevale, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Orangevale, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Santa Ana, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Stockton, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Stockton, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Tustin, CA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Tustin, CA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Jacksonville, FL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Pembroke Pines, FL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Augusta, GA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigator Site
mi
from
Chicago, IL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigator Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Peoria, IL
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Peoria, IL
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Baton Rouge, LA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Metairie, LA
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Chelsea, MI
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Chelsea, MI
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Royal Oak, MI
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Brooklyn Center, MN
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Brooklyn Center, MN
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
St. Peters, MO
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
St. Peters, MO
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Toms River, NJ
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Toms River, NJ
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Trenton, NJ
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Trenton, NJ
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Simpsonville, SC
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative site
mi
from
Dallas, TX
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated:  8/11/2015
Novartis Investigative Site
mi
from
Houston, TX
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension
Status: Enrolling
Updated: 8/11/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials